---
layout: post
title: "Conducting Remote Regulatory Assessments-Questions and Answers; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:59:57 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-15812
original_published: 2022-07-25 00:00:00 +0000
significance: 8.00
---

# Conducting Remote Regulatory Assessments-Questions and Answers; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 25, 2022 00:00 UTC
**Document Number:** 2022-15812

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Conducting Remote Regulatory Assessments--Question and Answers." FDA is issuing the draft guidance to describe the Agency's current thinking regarding its use of remote regulatory assessments (RRAs) in order to increase industry's understanding of RRAs and facilitate FDA's process for conducting RRAs. FDA has used RRAs to conduct oversight, mitigate risk, meet critical public health needs and help maximize compliance of FDA- regulated products. This draft guidance provides answers to frequently asked questions regarding what RRAs are, when and why FDA may use them, and how FDA may conduct them, among others.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/25/2022-15812/conducting-remote-regulatory-assessments-questions-and-answers-draft-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2022-15812

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
